FLT3LG Biologics Sequence Review Report 2026: Fms-related tyrosine kinase 3 ligand Similarity and Patent-Risk Signals

This FLT3LG Biologics Sequence Review Report was produced with PatSnap Biology Modality MCP workflows. It turns patent-scale sequence search, sequence retrieval, pairwise alignment and target evidence into a reproducible diligence narrative. Explore the PatSnap MCP servers used in this report.

Review date: 5 August 2026. This report supports R&D, competitive-intelligence and IP triage. It is not a legal opinion, freedom-to-operate conclusion or validity analysis. A sequence hit does not establish infringement, and a no-hit or low-hit result does not establish clearance.

Executive sequence-risk thesis

FLT3LG is a reviewed human protein asset represented by UniProt entry P49771. The reference sequence contains 235 amino acids and is annotated as Fms-related tyrosine kinase 3 ligand. PatSnap’s patent-scale screen returned 200 matching records in the configured result universe. The leading reviewed hit showed 100.00% query identity across 235/235, with the database claim annotation recorded as No.

The resulting screen is classified as moderate-to-elevated diligence priority. That label prioritizes diligence; it does not classify the asset as blocked, available or unique. Whole-protein identity can be driven by conserved domains, common signal peptides, transmembrane regions or endogenous human sequence. Patent relevance depends on whether live claims cover the complete sequence, a fragment, an engineered variant, an antibody recognizing the target, a use, or a functional genus.

Why this protein is a biologics-relevant review subject

Fms-related tyrosine kinase 3 ligand is a traceable human protein sequence suitable for systematic similarity screening. For biologics teams, the sequence can matter in several distinct ways: it may be the administered protein, an extracellular target, an antigen used to raise antibodies, a receptor domain incorporated into a fusion, or a reference against which engineered variants are defined. Those possibilities produce different patent questions even when they share the same gene symbol.

This report therefore separates sequence proximity from legal scope. A close patent-sequence match can identify families worth reading, yet naturally occurring human protein sequence is not itself a conclusion about enforceable rights. Conversely, engineered substitutions, truncations, Fc fusions, linkers, glycosylation-site changes or epitope-defined claims may be commercially important even when the full-length reference is not reproduced verbatim.

Biology Modality MCP evidence workflow

The workflow began with ls_sequence_search_submit against ALLPATENT protein records and used ls_sequence_search_get_results to retrieve the leading evidence. ls_sequence_fetch resolved the selected patent-sequence record, and ls_sequence_alignment performed a PSA comparison to the reviewed UniProt query. Finally, ls_antibody_antigen_search tested target-linked antibody evidence and ls_patent_sequence_fetch retrieved sequences from a resolved patent record where available.

Similarity-search readout

The leading result was evaluated under a supplementary sensitivity search using 50–100% identity and 50–100% query coverage. It reported 235/235 identical positions, query coverage 235/235, subject coverage 235/1006, E-value 7.97003e-164 and 0/235 gaps. The database marked the record as No for the claim annotation field.

The strict primary window did not yield a usable alignment within the initial service run, so this report also records a broader sensitivity screen. The broader result is explicitly secondary evidence and should not be compared directly with a strict-window hit without noting the threshold change.

The raw count of 200 records should not be read as the number of independent inventions. One sequence can appear in applications, grants, continuations, divisionals and multiple jurisdictions. It can also recur as a reference, antigen, control or prior-art comparator. Family consolidation by earliest priority, applicant, simple family and legal status is therefore essential before ranking competitive risk.

Sequence fetch and pairwise alignment

ls_sequence_fetch resolved sequence number 631383163 with a length of 1,006 aa. The fetched record was then supplied to ls_sequence_alignment for pairwise comparison with the reviewed FLT3LG sequence.

The PSA returned 1 alignment block(s). Reviewers should map mismatches to functional domains, extracellular segments, transmembrane regions, cleavage sites and engineered junctions. A concentrated change at a binding interface can matter more than a similar number of substitutions distributed across a nonfunctional region.

Antibody–antigen and patent-sequence evidence

The exact FLT3LG target-name query returned no antibody–antigen record in the configured page. This is an alias and coverage limitation, not evidence that the target lacks antibody activity or patent disclosure. Follow-up should include the full protein name, synonyms, development codes and pathway aliases.

No direct patent sequence bundle was resolved from the leading antibody–antigen record. This does not indicate an empty patent landscape. Relevant families may use different target aliases, functional definitions, percentage-identity language or sequence listings not connected to the first target record.

Target-level evidence complements sequence similarity because biologics patents often define inventions through binding, epitope, function, disease use or combinations rather than an exact full-length target sequence. The strongest review links the returned sequence to a patent family, verifies the role of the sequence in the specification, and then reads live claims in the jurisdictions relevant to development or commercialization.

Patent-risk interpretation

Diligence actions

1. Confirm the exact therapeutic or experimental construct, including isoform, truncation, signal peptide, tags, linkers and fusion partners.
2. Cluster high-ranking sequence records by patent family and earliest priority date rather than counting publications.
3. Retrieve the underlying sequence listings and confirm the biological role of each selected sequence number.
4. Map alignment differences to extracellular domains, binding interfaces, catalytic motifs and engineered junctions.
5. Search FLT3LG, Fms-related tyrosine kinase 3 ligand and known aliases in target, antibody, claim and assignee contexts.
6. Build jurisdiction-specific claim charts for live families and document licenses or collaboration rights.
7. Rerun the Biology Modality MCP workflow at the transaction or development decision date because database and legal-status coverage changes.

Bottom line

FLT3LG produced a traceable sequence-search result with 100.00% leading identity, 235/235 query coverage, 1 PSA block(s), 0 target-linked antibody records and 0 directly fetched patent sequences. Together, these signals support moderate-to-elevated diligence priority and a prioritized family-and-claim review. They do not support a binary clearance or infringement statement.

Explore PatSnap Open Platform MCP Servers to produce sequence similarity and patent-risk reports for antibodies, proteins, peptides and nucleic-acid assets.

Sources and methodology notes

Reference sequence metadata: reviewed human UniProt entry P49771. Patent-scale similarity, sequence detail, PSA, patent-sequence and antibody–antigen evidence was retrieved through PatSnap Biology Modality MCP on 5 August 2026. Results are bounded by the configured query, thresholds, aliases, task limits and database coverage; rerun at the decision date.